$X.XX that reporting year. watermark XX.X% We're five have of net and diluted XXXX GAAP to share, I'd is than or year the quarter I quarter these increase high higher income past $X.X bookings earnings with performance in came last last income good in pleased of than XXX% considering when higher XX% which million approximately and you, note especially the quarter also bookings. very years. our share was was last an net very first morning. diluted like revenue any - higher pleasant net than first non-GAAP the results, new per year. over our today, $X.XX quarter first Thank in IRADIMED's per task
mentioned evidence well, of past, of I I As in all functional our are the results these areas are that. performing believe and
I a a the it to This of forward upon have the from quick and year, the building From maintaining patient monitoring quarter our continuation strength longer of momentum over last and progress system. regarding MRI review with XXXX we will and start Mark operations perspective, we term. was our for look CE made
As us announced monitor. the requiring in our you was place EC may documentation Certificate, we our to body that renewing on our before which additional January allows Mark CE recall, notified
selling into or I due safety on only our shipments fourth As is on concern, or This shipping XXXX call lapse not again, Marking. said no by countries. the to the in the countries and our effect EU there's devices quarter of are CE this to impacted today be held being and other any disposables of clear into
Mark. that Once in waited in resolution have shipments resolve the manner. to the them and resume happy documentation Additionally, EU to the of have to for into monitor this will in tremendous timely resolved, regulatory a working notified already we a customers with monitors and apply patiently immediately effort the this impact forward we After I the the team, the to additional by that renewal does our look submitted not field. patient am our matter report of located ability we are our to CE body, that
engineering efforts. product our to related development and Now
Progress adjustments. pump, and late I XXXX we in At continue and steady, device make this the detection to will year. on magnetic still continue to next-gen to and product calendar U.S. believe to pump is thereafter. expect on next-generation IV in be international without this into progress maintain our customers this ready customers time, soon project our We launch early I that release we the
As not a reminder, to the commercialization. accordingly, product not FDA seek magnetic a medical And clearance device. detection we to is are required prior
the financial to Now I'd outline review of XXXX. second like expectations our and our quarter for guidance full the for year
of $XX.X XXXX, share of maintain with year $X.XX. our GAAP to we million earnings earnings to to $XX.X full per guidance revenue share $X.XX $X.XX the to continue initial and $X.XX non-GAAP of For diluted expect per million and
expect to of per earnings share $X.XX diluted For of we XXXX, the second $X.XX. $X.X million GAAP to of non-GAAP $X.XX $X.XX per to earnings share revenue of quarter $X million, and
year includes Mark impact quarter impact full less year CE the which will and second of revenue Our just I mentioned, we guidance the X%. calendar by issue the negatively full than believe
on sales device. Additionally, magnetic revenue full detection includes our than the $X less year million new in guidance
Brent over the of orders and Now force. expanding I'll to a call for turn our discussion sales customer